The Acral Lentiginous Melanoma drugs in development market research report provides comprehensive information on the therapeutics under development for Acral Lentiginous Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acral Lentiginous Melanoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acral Lentiginous Melanoma and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Acral Lentiginous Melanoma by nine companies/universities/institutes. The top development phase for Acral Lentiginous Melanoma is phase ii with five drugs in that stage. The Acral Lentiginous Melanoma pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Acral Lentiginous Melanoma pipeline products market are: Regeneron Pharmaceuticals, Novartis and GSK.
The key targets in the Acral Lentiginous Melanoma pipeline products market include Programmed Cell Death Protein 1, Proto Oncogene Tyrosine Protein Kinase Receptor Ret, and Receptor Tyrosine Protein Kinase ERBB 3.
The key mechanisms of action in the Acral Lentiginous Melanoma pipeline product include Programmed Cell Death Protein 1 Antagonist with three drugs in Phase III. The Acral Lentiginous Melanoma pipeline products include four routes of administration with the top ROA being Intravenous and three key molecule types in the Acral Lentiginous Melanoma pipeline products market including Monoclonal Antibody, and Small Molecule.
Acral Lentiginous Melanoma overview
Acral lentiginous melanoma (ALM), also sometimes referred to as, simply, acral melanoma, is melanoma occurring on the hands and feet (palms, soles, fingers, toes, and nail units). This is is a subtype of cutaneous malignant melanoma. The condition can develop in normal-appearing skin or within an existing mole. It is comprised of malignant melanocytes, which can become invasive with time.
For a complete picture of Acral Lentiginous Melanoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
